Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for XELOX-associated thrombocytopenia in colorectal cancer
ChiCTR2400093819Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Sichuan Cancer Hospital. Primary endpoint: Time to first platelet count recovery to 100 × 10^9/L. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2400093819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093819.